Comprehensive rationale for the use of immune plasma for septic patients

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract


Data of accounting and reporting documents of the Center (blood and tissues) are analyzed retrospectively) the Kirov military medical Academy for the period from 2017 to 2019 on the use of blood components in septic conditions of patients in clinics of the Kirov Military medical Academy. The volume of issued immune plasma for patients suffering from septic complications in2017, it was 154 doses (33,9 l), in 2018, it was 196 doses (43,1 l), in 2019, it was 389 doses (72,1 l). It was found that in patients suffering from septic complications on the second day after transfusion of blood components, the levels of the studied indicators of the inflammatory process did not change unambiguously. Thus, in patients who received immune plasma transfusion, there was a decrease in white blood cells by 1,5×109/l on the next day after the component was transfused. At the same time, there was a direct decrease in rod-shaped neutrophils, monocytes, erythrocyte sedimentation rate and a decrease in body temperature. In patients who were transfused fresh frozen plasma, white blood cells increased by 0,5×109/l and slightly - monocytes. A slight decrease in platelets in septic patients of group 1 after transfusion of immune plasma indicates the active participation of these cells in the reactions of antibacterial immunity. This can be considered as a favorable prognosis for a particular patient, since there is a direct relationship between the decrease in the number of platelets and the duration of stay in hospital treatment, as well as the overall outcome of the disease. The level of circulating immune complexes in patients of both groups after transfusions of blood components remained within normal values. Levels of fibrinogen, prothrombin, and albumin changed significantly in each group. At the same time, the level of fibrinogen after transfusions increased, and prothrombin changed in different directions. In the treatment of patients, the use of immune plasma activates the system of cells of the body’s antibacterial defense and improves the positive dynamics in treatment. In modern economic realities, testing plasma samples to suppress the growth of microbial colonies is justified, since it helps to reduce the volume of transfused blood components for severe septic patients.

Full Text

Restricted Access

References

  1. Козлов, В.К. Сепсис: этиология, иммунопатогенез, концепция современной иммунотерапии / В.К. Козлов. - СПб.: Диалект, 2008. - 24 с.
  2. Руднов, В.А. Сепсис-3: обновленные ключевые положения, потенциальные проблемы и дальнейшие практические шаги / В.А. Руднов [и др.] // Вестн. анестезиол. и реаниматол. - 2016. - № 4 (13). - С. 5.
  3. Руднов, В.А. Сепсис и терагностика на пути к персонализированной медицине / В.А. Руднов [и др.] // Вестн. анестезиол. и реаниматол. - 2015. - № 6. - С. 60-67.
  4. Серебряная, Н.Б. Роль тромбоцитов в патогенезе бактериальных инфекций / Н.Б. Серебряная [и др.] // Журн. инфектолог. - 2017. - № 4 (9). - С. 5-8.
  5. Серебряная, Н.Б. Тромбоциты как активаторы и регуляторы воспалительных и иммунных реакций. Ч. 2. Тромбоциты как участники иммунных реакций / Н.Б. Серебряная [и др.] // Мед. иммунолог. - 2019. - № 1 (21). - С. 14.
  6. Тец, В.В. Микроорганизмы и антибиотики. Заболевания мочевыводящих путей / В.В. Тец. - СПб.: КЛЕ-Т, 2005. - 27 с.
  7. Hagihara, М. Platelets, after exposure to a high shear stress, induce IL-10-producing, mature dendritic cells in vitro / М. Hagihara [et al.] // J. Immunol. - 2004. - № 9 (172). - Р. 5297-5303.
  8. Halvorsen, В. Activated platelets promote increased monocyte expression of CXCR5 through prostaglandin E2-related mechanisms and enhance the anti-inflammatory effects of CXCL13 / В. Halvorsen [et al.] // Atheroscleros. - 2014. - № 2 (234). - Р. 352-359.
  9. Iskander, K. N. Sepsis: multiple abnormalities, heterogeneous responses and evolving understanding / K. N. Iskander [et al.] // Physiol. Rev. - 2013. - № 3 (93). - P. 247-1288.
  10. Kwan, A. Transcriptional instability during evolving sepsis may limit biomarker based risk stratification / A. Kwan [et al.] // PL. On. - 2013. - № 3 (8). - Р. 460-501.
  11. Singer, M. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016 / М. Singer [et al.] // Critic. Car. Medic. - 2017. - № 3 (45). - Р. 503.
  12. Zamora, С. Functional consequences of platelet binding to T lymphocytes in inflammation / С. Zamora [et al.] // J. Leukoc. Biol. - 2013. - № 3 (94). - Р. 521-529.

Statistics

Views

Abstract - 10

PDF (Russian) - 0

Cited-By


Article Metrics

Metrics Loading ...

PlumX

Dimensions


Copyright (c) 2020 Skripay L.A., Vilyaninov V.N., Skripay A.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies